Implementation

• High Alert: Fatalities have occurred with chemotherapeutic agents. Before administering, clarify all ambiguous orders; double check single, daily, and course-of-therapy dose limits; have second practitioner independently double check original order, calculations, and infusion pump settings. Alemtuzumab should only be administered under the supervision of a physician experienced in the use antineoplastic therapy

• Administer via IV only. Inspect solution for particulate matter or discoloration. Do not administer solutions that contain particulate matter or are discolored

• Withdraw necessary amount from ampule into syringe. Filter with a sterile low-protein binding, non-fiber releasing 5 micron filter prior to dilution

• Intermittent Infusion:
Diluent: Dilute with 100 ml of 0.9% NaCl or D5W. Gently invert bag to mix. Dispose of syringe and unused drug product according to institutional guidelines. Use within 8 hr of dilution. Store at room temperature or in refrigerator. Protect solution from light

• Rate:
Administer over 2 hr

• Y-Site Incompatibility:
No data is available regarding mixing with other solutions and medications. Do not add to or infuse simultaneously with other solutions or medications

alemtuzumab is a sample topic found in Davis's Drug Guide. All other sections of this record are viewable by clicking on the index in the left column, or by clicking on "Display all Sections" in the "Content Manager".

To find other Davis's Drug Guide topics, please login or purchase a subscription.